This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit May. 10, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management

Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.

Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.

Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!

Save the Date:
Fall Managed Care Forum
November 8-9
Bellagio Hotel



Cystic fibrosis treatment is deemed 'game-changing'
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Vertex Pharmaceuticals' new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease, led to significantly improved breathing ability in a mid-stage study. The data suggested Vertex could have a multibillion-dollar franchise in cystic fibrosis, a life threatening genetic disorder that affects about 70,000 people worldwide. More

What is the Health Economic Impact of a Non-Invasive Prenatal Test?

Learn About Bridgehead International’s report, authored by Susan Garfield, on the clinical and economic utility of this test in this quarter’s JMCM, entitled “Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies.

Genetic literacy poor in primary care
Canadian Medical Association Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Despite early predictions of huge public demand for direct-to-consumer genetic testing, it's safe to say personal genetic data isn't clogging the postal system in quantities large enough to predispose mail carriers to back pain. Still, many health experts suggest genetics remains poised to play a larger role in day-to-day medicine. While that may sound encouraging to companies that make genetic tests, it's likely less so for family physicians with poor genetic literacy. More

GlaxoSmithKline to go hostile with $2.6 billion Human Genome offer
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. GSK and the U.S. pioneer of gene-based drug discovery sell Benlysta together and the companies are collaborating on two other experimental drugs in late-stage trials for diabetes and heart disease that could become significant sellers. More

 Biotech/Diagnostics/Personalized Medicine

AssureRx introduces new pharmacogenomic test for ADHD
The Medical News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
AssureRx Health announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder. The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications. More

No such thing as a 'normal vagina?'
TIME    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Perhaps it need not be said that one vagina is not the same as the next, but medically speaking, doctors have long thought that all "healthy" vaginas had certain things in common — namely levels of some good bacteria. "With the microbiome of the vaginal communities, we can start thinking about personalized medicine for women," one doctor said. More


Nursing@Georgetown is a Master’s in Nursing program delivered online by Georgetown University’s renowned School of Nursing & Health Studies.
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE

 Regenerative Medicine

New York medical schools chart progress with stem cells
The Associated Press via CBS News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Almost halfway through a $600 million state program supporting stem cell research, eight medical schools around New York are reporting progress on projects such as replicating liver cells and eradicating leukemia cells. A new report from Associated Medical Schools of New York updates work at the institutions where hundreds of researchers are starting to unravel causes and potential treatments for conditions ranging from autism to heart disease and cancer. More

Stem cells poised to self-destruct for good of the embryo
PhysOrg    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Embryonic stem cells — those revered cells that give rise to every cell type in the body — just got another badge of honor. If they suffer damage that makes them a threat to the developing embryo, they swiftly fall on their swords for the greater good, according to a study published in the journal Molecular Cell. More

 Emerging Medical Technologies

Breathalyzer detects disease thanks to nonwires
Medgadget    Share    Share on FacebookTwitterShare on LinkedinE-mail article
VideoBriefResearchers at Stony Brook University in New York have developed a breath analyzing device that can quickly identify a number of disease marker gases that could be signs of an underlying problem. The technology utilizes single crystal nanowires that are created by electrospinning. More

Incisionless antiobesity device makes early close of $3.1 million
MedCity News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A company developing an incisionless, implantable antiobesity medical device has made an early close of $3.1 million on a series B round of investment that's expected to reach $5 million. Ohio-based EndoSphere will use the series B to commercially launch its Satisphere innovative medical device, which received the CE Mark recently. Additionally, EndoSphere plans to conduct post-clinical market followup studies of the device. More

 Managed Healthcare News

Long-term-care insurance: Who needs it?
NPR    Share    Share on FacebookTwitterShare on LinkedinE-mail article
VideoBriefAmericans routinely buy all sorts of insurance — for cars, homes, health and even pets and boats. But when it comes to long-term-care insurance, relatively few sign up. Out of more than 313 million Americans, only about 8 million have any such protection, according to the American Association for Long-Term Care Insurance. The low participation rate largely reflects the high cost of long-term-care insurance. More

Dual-eligibles pilot program faces rush from states
Modern Healthcare    Share    Share on FacebookTwitterShare on LinkedinE-mail article
States want to include more than three million dual-eligible beneficiaries in a CMS pilot program to overhaul their care and payments. The number is one million more than the program was designed for and represents about a third of all that category's beneficiaries, whose care is one of the biggest drivers of the growth in Medicaid costs. More

 FDA: New Treatments and Technology

FDA staff: Pfizer arthritis pill raises safety concerns
Bloomberg Businessweek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pfizer's experimental pill to treat rheumatoid arthritis, one of the company's leading drug candidates, raised "serious safety concerns" in trials, U.S. regulators said. The pill, tofacitinib, carried increased risks of serious infections and malignancies, in particular a higher chance of lymphoma, Food and Drug Administration staff wrote. More

Collaboration seeks to find new uses for failed drugs
The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The U.S. government is looking for the next AZT, Viagra and thalidomide — substances that washed out as treatments for one disease but later turned out to work well against a totally different ailment. The National Institutes of Health and three large pharmaceutical companies hope there are dozens of other failed drugs waiting to be rescued and repurposed. They recently announced a collaboration to look for them. More

"There are more than 100 different types of arthritis, according to the National Library of Medicine. And a recent study found arthritis affects 57 percent of adults with heart disease, the Arthritis Foundation states."
Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
May 3, 2012
April 26, 2012
April 19, 2012
April 12, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063